General Information
Version
8.4
Revision date
2024-01-03
Product name
Pregabalin impurity B
CAS No.
148553-51-9
REACH No
A
Emergency telephone
+(45)-6991 8573, +(45)-8212 1212
Icons in SDS
Company Information
company name
Merck Life Science ApS
e-mail address of the competent person responsible for the Safety Data Sheet
TechnicalService@merckgroup.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H336, H361
Hazard statements
Code
Statements
H336
May cause drowsiness or dizziness
Section 2
SECTION 2: Hazards identification
2.1 Classification of the substance or mixture
Reproductive toxicity, (Category H361: Suspected of damaging fertility or 2) the unborn child. Specific target organ toxicity - H336: May cause drowsiness or dizziness. single exposure, (Category 3), Central nervous system
Signal word
Warning Warning
Hazard statements
H336 May cause drowsiness or dizziness. H361 Suspected of damaging fertility or the unborn child. H361 Suspected of damaging fertility or the unborn child.
Precautionary statements
P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P261 Avoid breathing dust/ fume/ gas/ mist/ vapors/ spray. P271 Use only outdoors or in a well-ventilated area. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 IF exposed or concerned: Get medical advice/ attention. P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 IF exposed or concerned: Get medical advice/ attention.
Supplemental label elements
none Reduced Labeling (<= 125 ml) none
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
